Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 2/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | CHRNA1 | P02708 | 4/20 | 0.32 |
| ▸ | CHRNG | P07510 | 4/20 | 0.32 |
| ▸ | CHRNB1 | P11230 | 4/20 | 0.32 |
| ▸ | CHRND | Q07001 | 4/20 | 0.32 |
| ▸ | GLS | O94925 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 2/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | HRH2 | P25021 | 1/20 | 0.30 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.30 |
| ▸ | TOP2A | P11388 | 1/20 | 0.30 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6286550 | 0.87 | MAPT (0.32) | LTA4H | |
| SCHEMBL6282776 | 0.85 | EGFR (0.35) | CNR1EGFRCNR2 | |
| Hydrochloric Acid SCHEMBL6286600 | 0.80 | CHRNA1 (0.37) | CHRNA1CHRNGCHRNB1CHRNDGLS | |
| SCHEMBL6286413 | 0.78 | MEN1 (0.31) | — | |
| SCHEMBL6290435 | 0.78 | EGFR (0.34) | EGFR | |
| SCHEMBL6290421 | 0.78 | EGFR (0.34) | EGFR | |
| Hydrochloric Acid SCHEMBL6287860 | 0.75 | LTA4H (0.33) | LTA4H | |
| Trifluoroacetic Acid SCHEMBL7038495 | 0.74 | TP53 (0.35) | — | |
| Trifluoroacetic Acid SCHEMBL6288018 | 0.73 | CES1 (0.39) | EPHX2CNR2LTA4H | |
| Trifluoroacetic Acid SCHEMBL6286281 | 0.73 | CES1 (0.39) | EPHX2CNR2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6887890-B2 | Compounds exhibiting thrombopoietin-like activities | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-05-03 | — | — | US | disclosed |
| US-20030162724-A1 | Compounds exhibiting thrombopoietin-like activities | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-08-28 | — | — | US | disclosed |
| EP-1291341-A1 | COMPOUNDS EXHIBITING THROMBOPOIETIN-LIKE ACTIVITIES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-03-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162724-A1 | Compounds exhibiting thrombopoietin-like activities | MPL, THPO, TEK | EPHX2 2588/4885CNR1 1813/4885EGFR 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.